Oral administration of medicinal products containing buflomedil: EMA recommends suspension of marketing authorisation
2011.05.26
Active substance: buflomedil
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended suspending the marketing authorisation for oral use of medicines containing buflomedil in EU Member States.
risk information - full text (available in German only)